HomeCompareABOT vs MRK

ABOT vs MRK: Dividend Comparison 2026

ABOT yields 0.34% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $36.6K in total portfolio value
10 years
ABOT
ABOT
● Live price
0.34%
Share price
$33.21
Annual div
$0.11
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.1K
Annual income
$34.74
Full ABOT calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ABOT vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABOTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABOT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABOT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABOT
Annual income on $10K today (after 15% tax)
$28.89/yr
After 10yr DRIP, annual income (after tax)
$29.53/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,298.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABOT + MRK for your $10,000?

ABOT: 50%MRK: 50%
100% MRK50/50100% ABOT
Portfolio after 10yr
$38.5K
Annual income
$4,916.44/yr
Blended yield
12.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ABOT
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABOT buys
0
MRK buys
0
No recent congressional trades found for ABOT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABOTMRK
Forward yield0.34%2.76%
Annual dividend / share$0.11$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$20.1K$56.8K
Annual income after 10y$34.74$9,798.13
Total dividends collected$344.00$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ABOT vs MRK ($10,000, DRIP)

YearABOT PortfolioABOT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,734$33.98$11,206$366.19$472.00MRK
2$11,519$34.09$12,650$502.35$1.1KMRK
3$12,360$34.19$14,407$694.19$2.0KMRK
4$13,259$34.29$16,585$967.82$3.3KMRK
5$14,222$34.38$19,342$1,363.89$5.1KMRK
6$15,252$34.46$22,913$1,947.19$7.7KMRK
7$16,354$34.54$27,662$2,823.89$11.3KMRK
8$17,534$34.61$34,159$4,173.35$16.6KMRK
9$18,796$34.68$43,337$6,308.80$24.5KMRK
10$20,146$34.74$56,776$9,798.13$36.6KMRK

ABOT vs MRK: Complete Analysis 2026

ABOTStock

ABOT invests in US companies of all market capitalization that exhibit strong free cash flow and innovation. These companies are those that represents the top 25% of the eligible universe based on (1) quality of earnings (2) profits generated from R&D (3) degree of R&D investment relative to total assets (4) assets turnover and (5) financial leverage. Target weight is allocated to each security based on the combination of the five factors and market cap. Based on the target weight, the index selects up to 120 names or until 90% of the cumulative security weight has been included, whichever occurs first. Prior to Nov. 29, 2021, the fund was named TrimTabs Donoghue Forlines Risk Managed Innovation ETF and tracked TrimTabs Donoghue Forlines Risk Managed Free Cash Flow Innovation Index. Also, prior to Nov. 7, 2023, the fund was named Donoghue Forlines Risk Managed Innovation ETF, tracked FCF Risk Managed Quality Innovation Index, and implemented a risk-managed downside protection model. Prior to Nov. 13, 2024 the fund name was Donoghue Forlines Innovation ETF and traded under the ticker DFNV.

Full ABOT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ABOT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABOT vs SCHDABOT vs JEPIABOT vs OABOT vs KOABOT vs MAINABOT vs JNJABOT vs ABBVABOT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.